Comparison of two chemotherapy regimens, with or without cyclosporin A, in relapsed/refractory acute myeloid leukaemia: Results of the UK Medical Research Council AML-R trial.

被引：0
|
作者：
Yin, JAL
Wheatley, K
Rees, J
Burnett, A
机构：
[1] Manchester Royal Infirm, Manchester M13 9WL, Lancs, England
[2] CTSU Oxford, Oxford, England
[3] Addenbrookes Hosp, Cambridge, England
[4] Univ Wales Coll Med, Cardiff CF4 4XN, S Glam, Wales
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
946
引用
收藏
页码：231A / 231A
页数：1
相关论文
共 50 条
  • [31] Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
    Cortes, Jorge E.
    Khaled, Samer
    Martinelli, Giovanni
    Perl, Alexander E.
    Ganguly, Siddhartha
    Russell, Nigel
    Kraemer, Alwin
    Dombret, Herve
    Hogge, Donna
    Jonas, Brian A.
    Leung, Anskar Yu-Hung
    Mehta, Priyanka
    Montesinos, Pau
    Radsak, Markus
    Sica, Simona
    Arunachalam, Meena
    Holmes, Melissa
    Kobayashi, Ken
    Namuyinga, Ruth
    Ge, Nanxiang
    Yver, Antoine
    Zhang, Yufen
    Levis, Mark J.
    LANCET ONCOLOGY, 2019, 20 (07): : 984 - 997
  • [32] Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
    Cortes, Jorge E.
    Ganguly, Siddhartha
    Khaled, Samer K.
    Kramer, Alwin
    Levis, Mark J.
    Martinelli, Giovanni
    Perl, Alexander E.
    Russell, Nigel H.
    Botteman, Marc
    Shah, Ruchit
    Luo, Linlin
    Shun, Zhenming
    Ray, Saurabh
    BLOOD, 2019, 134
  • [33] Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. (vol 11, pg 429, 2010)
    Moorman, A., V
    Ensor, H. M.
    Richards, S. M.
    LANCET ONCOLOGY, 2010, 11 (06): : 516 - 516
  • [34] Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
    Cutting, Robert J.
    Richards, Sue
    Hancock, Jeremy
    Goulden, Nicholas
    Mitchell, Christopher D.
    Vora, Ajay J.
    BLOOD, 2008, 112 (11) : 539 - 540
  • [35] Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML)
    Levis, Mark J.
    Perl, Alexander E.
    Altman, Jessica K.
    Cortes, Jorge E.
    Ritchie, Ellen K.
    Larson, Richard A.
    Smith, Catherine Choy
    Wang, Eunice S.
    Strickland, Stephen Anthony
    Baer, Maria R.
    Litzow, Mark Robert
    Claxton, David
    Schiller, Gary J.
    Ustun, Celalettin
    Liu, Charles
    Gill, Stan
    Sargent, Briana
    Bahceci, Erkut
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
    Perl, Alexander E.
    Martinelli, Giovanni
    Cortes, Jorge E.
    Neubauer, Andreas
    Berman, Ellin
    Paolini, Stefania
    Montesinos, Pau
    Baer, Maria R.
    Larson, Richard A.
    Ustun, Celalettin
    Fabbiano, Francesco
    Di Stasi, Antonio
    Stuart, Robert
    Olin, Rebecca
    Kasner, Margaret
    Ciceri, Fabio
    Chou, Wen-Chien
    Podoltsev, Nikolai
    Recher, Christian
    Yokoyama, Hisayuki
    Hosono, Naoko
    Yoon, Sung-Soo
    Lee, Je-Hwan
    Pardee, Timothy
    Fathi, Amir T.
    Liu, Chaofeng
    Liu, Xuan
    Bahceci, Erkut
    Levis, Mark J.
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
    Cutting, R. J.
    Richards, S.
    Hancock, J.
    Goulden, N.
    Mitchell, C. D.
    Vora, A. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 46 - 47
  • [38] Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial
    Moorman, Anthony V.
    Ensor, Hannah M.
    Richards, Sue M.
    Chilton, Lucy
    Schwab, Claire
    Kinsey, Sally E.
    Vora, Ajay
    Mitchell, Chris D.
    Harrison, Christine J.
    LANCET ONCOLOGY, 2010, 11 (05): : 429 - 438
  • [39] Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results
    Qi, Junyuan
    Wei, Xudong
    Li, Qiubai
    Chang, Chukang
    Zhou, Fuling
    Huang, Jianying
    Zhang, Yu
    Xu, Chongyuan
    Tang, Xiaowen
    Jiang, Qian
    Li, Junmin
    Qin, Qun
    He, Qun
    Gao, Sujun
    Liu, Liping
    Chen, Zi
    Yu, Min
    Wang, Jing
    Men, Lichuang
    Wang, Hengbang
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    Wang, Jianxiang
    BLOOD, 2023, 142
  • [40] Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/ Refractory Acute Myeloid Leukemia (R/R AML)
    Perl, Alexander E.
    Altman, Jessica K.
    Cortes, Jorge E.
    Smith, Catherine C.
    Litzow, Mark
    Baer, Maria R.
    Claxton, David F.
    Erba, Harry P.
    Gill, Stanley C.
    Goldberg, Stuart L.
    Jurcic, Joseph G.
    Larson, Richard A.
    Liu, Charles
    Ritchie, Ellen K.
    Schiller, Gary J.
    Spira, Alexander I.
    Strickland, Stephen A.
    Tibes, Raoul
    Ustun, Celalettin
    Wang, Eunice S.
    Stuart, Robert K.
    Rollig, Christoph
    Neubauer, Andreas
    Martinelli, Giovanni
    Bahceci, Erkut
    Levis, Mark J.
    BLOOD, 2016, 128 (22)
12345